Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)

Inclusion Criteria:

• Age 45-85

• Diagnosis of mild to moderate AD

• Clinical laboratory values within normal range or < 1.5 times ULN

• If receiving AD-specific treatment, have been on stable dose for ≥ 3 months prior tofirst dose of study drug.

• Life expectancy of >2 years

• Able and willing to provide written informed consent

Exclusion Criteria:

• Any physical or psychological condition that prohibits study completion

• Known cardiac disease

• Active or history of malignancy in the past 5 years

• Serious infection that will not be resolved by first day of study intervention.

• History of clinically significant CNS event or diagnosis in the past 5 years.

• Acute illness within 30 days of Day 1

• History of suicidal behavior or suicidal ideation

• History of chronic alcohol use or substance abuse in the last 5 years

• HIV, hepatitis B and/or hepatitis C positive

• Vaccines within 14 days

• Receipt of investigational products within 30 days

• Blood donation within 30 days

• Pregnant or breastfeeding